Novo Nordisk was sent a warning letter from the FDA for a series of violations of postmarketing adverse drug experience regulations, including failure to report side effects among patients using its GLP-1 drugs for diabetes and weight loss. GLP-1 drugs have also been widely claimed to help reduce substance abuse.
Search
News Archives
News Signup
FREE: daily or weekly news supporting freedom from dependency
Journal signup
FREE: print journal and emag supporting freedom from dependency
Conference savings
MONEY OFF: for signups
Support our work
To support us giving the recovery field FREE daily news+research, FREE library, FREE journal and subsidised conference training, click the secure Donate link. THANK YOU!
Recent News
